New guidance for osteoporosis management


  • Mary Corcoran
  • Univadis Medical News
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

A new guidance document has been published on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures.

The paper summarises recent guidance published by International Osteoporosis Foundation (IOF) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) for the diagnosis and management of osteoporosis “in an international setting” with a focus on the categorisation of risk as a strategy to target therapeutic interventions.

The rationale for the more refined characterisation of risk is to offer the most appropriate interventions to the patient. For example, the authors say initial treatment recommendations for women at high risk might most suitably be with an inhibitor of bone resorption. In contrast, women at very high risk (or 'imminent risk' of fracture) might be more suitably treated with an anabolic treatment followed thereafter by an inhibitor of bone resorption. Non-pharmacological treatment should be considered for all patients, but adapted to their category, the authors add. 

Professor Jean-Yves Reginster, ESCEO president and co-author said: "The publication addresses the need for succinct guidance that will help clinicians identify and treat women at the very highest risk as early as possible.” 

The guidance is published in Osteoporosis International